JPRN-UMIN000016087招募中2 期
Efficasy and safety of bevacizumab in combination with chemotherapy for treating the first recurrence of ovarian carcinoma : Phase 2 study - Efficasy and safety of bevacizumab in combination with chemotherapy for treating the first recurrence of ovarian carcinoma : Phase 2 study
Yokohama city univesity Obstetrics and Gynecology0 个研究点目标入组 25 人开始时间: 2015年1月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •(1)Patients with serious complications(such as uncontrolled diabetes) (2)Patients with below such severe heart disease congestive heart failure uncontrolled arrhythmia uncontrolled hypertension angina pectoris valvular heart disease (3)Patients with abdominal fistula of history, gastrointestinal perforation, intra-abdominal abscess,the symptoms of intestinal obstruction can not been able oral nutrition not-healing wounds, ulcers,fractions bleeding diathesis and significant coagulopathy Period of up to study treatment start from major surgery effective date is in the next 28 days,it is in the urine protein +2 or more at the time and registration (4) Patients with interstitial pneumonia or pulmonary fibrosis (5)patients with a history of severe drug hypersensitivity and drug allergy (6)Other, patients attending physician has determined that inadequate to safely carry out the present study
研究者
相似试验
进行中（未招募）
1 期
Assessment of the efficacy of bevacizumab in combination with Folfiri as second-line treatment after the failure of the cisplatin (or carboplatin)-etoposide combination in patients suffering from an advanced inoperable poorly differentiated neuroendocrine carcinoma of an unknown or gastroentero-pancreatic primary cancer. A phase 2 non-comparative randomized study. PRODIGE 41 - BEVANEC studyeuroendocrine carcinomaMedDRA version: 20.0Level: PTClassification code 10057270Term: Neuroendocrine carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001305-16-FRHospices Civils de Lyon - Direction de la Recherche Clinique et de l'Innovation
招募中
不适用
A clinical study of Bevacizumab therapy in combination with chemotherapeutic drugs for children with recurrent gliomaJPRN-UMIN000005528Osaka University Graduate School of Medicine12
进行中（未招募）
不适用
Phase II study of the combination of Bevacizumab (rhuMab VEGF) plus Capecitabine with pre-operative standard radiotherapy in patients with locally advanced rectal cancer.Patients with locally advanced, non metastatic, resectable primary rectal cancer stage cT3 or cT4 who are subject to combined chemotherapy of the pelvic region in the pre-operative setting.MedDRA version: 14.1Level: PTClassification code 10038038Term: Rectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-000802-30-ITROCHE
进行中（未招募）
不适用
Phase II clinical study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic breast cancerMetastatic or locally recurrent HER2-negative breast cancerMedDRA version: 12.0Level: LLTClassification code 10055113Term: Breast cancer metastaticMedDRA version: 12.0Level: LLTClassification code 10006198Term: Breast cancer recurrentEUCTR2009-016062-82-HUSOUTH EASTERN EUROPEAN RESEARCH ONCOLOGY GROUP88
招募中
2 期
A PhaseII Study of Bevacizumab in Combination with S-1 in Patients with Non-Squamous Non-Small-Cell Lung Cancer reviously treated with platinum based chemotherapyon-Squamous Non-Small-Cell Lung CancerJPRN-UMIN000005486Hiroshima citizens hospital Department of Medical Oncology34